Multiple Myeloma , Plitidepsin (Aplidin® PharmaMar) will be re-evaluated by the EMA FARMACOLOGIA HEALTH U.S. ONCOLOGIA POLITICA SANITARIA Multiple Myeloma , Plitidepsin (Aplidin® PharmaMar) will be re-evaluated by the EMA Redazione 9 Luglio 2024 PharmaMar (MSE:PHM) has received a notification from the European Commission (EC) informing the Company of its decision... Per saperne di più Maggiori informazioni su Multiple Myeloma , Plitidepsin (Aplidin® PharmaMar) will be re-evaluated by the EMA
